Lila Biologics Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel radioligand therapies for imaging and treatment of solid tumors.
Technische Universität München has described conjugates comprising a silicone-based fluoride acceptor (SiFA)-based peptide targeting moiety covalently linked to radiolabeled chelating agents through a divalent linker.
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has identified drug-conjugates comprising a radionuclide-labeled molecular probe linked to ligand targeting fibroblast activation protein α (FAP) through a linker reported to be useful for the treatment and diagnosis of cancer.
Hepatocellular carcinomas (HCCs) are challenging to diagnose due to the tumor heterogeneity and unnoticeable early symptoms. Researchers from Anhui Medical University have developed a novel gallium 68 (68Ga)-labeled radiotracer, named [68Ga]DOTA-AngII, designed to improve the precision of HCC imaging.
Deep learning tools for protein design can also be used to create molecules that bind to them. Certain peptides, such as intrinsically disordered proteins (IDPs), are challenging to target due to their variable nature. However, scientists from the lab of Nobel laureate David Baker have developed a method to generate binders for IDPs by searching the world’s largest protein database with their AI-powered tool RFdiffusion.
One of the functions of tumor-associated macrophages (TAMS) is to protect the tumor against the immune system, inhibiting T-cell engagement and reducing the efficacy of checkpoint inhibitors. Polyamidoamine hydroxyl dendrimers (HDs) target TAM without the need of a targeting ligand and are retained by TAMs for up to 1 month allowing radiation to deposit in the tumor.
Carbonic anhydrase IX (CAIX, CA9) is a membrane-associated isoform of the α-carbonic anhydrase enzyme family, involved in pH regulation and the acidification of the tumor microenvironment (TME) in solid tumors. It is widely recognized as a marker of tumor hypoxia and serves as a prognostic indicator in multiple human cancers.
Chinese researchers from Huazhong University of Science and Technology have developed a novel carbonic anhydrase IX (CAIX)-targeting radiotracer, [68Ga]NXK-44, for the imaging of hypoxic tumors and renal cell carcinoma (RCC).
Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter probe for imaging neuroinflammation in preclinical models of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by inflammatory cell infiltration, demyelination and axonal damage.
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer.
RSS
